Assembly Biosciences is a clinical-stage biotechnology company developing therapeutics for serious viral diseases including herpes simplex virus, hepatitis B and D viruses, and transplant-associated herpesviruses. The company's pipeline comprises four programs with mechanism-driven novel compounds at various clinical stages, addressing large unmet medical needs where current therapies have limited efficacy, high pill burden, or no new treatments approved in decades. Assembly generates revenue through partnerships with established pharmaceutical companies, receiving upfront and milestone payments plus royalties on successful commercialization, while leveraging external manufacturing and clinical trial partners to maintain an efficient operating model.